

Freedom of Information Team
De La Court House
Queen Alexandra Hospital
Southwick Hill Road
Portsmouth
Hampshire
PO6 3LY

Date: 23/05/2022

Ref: 21-22 632

Freedom of Information request

Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 10/02/2022. Please see responses to your requests below.

1. How many patients have been diagnosed with advanced hepatocellular carcinoma (Stage 3b and 4) in the last 6 months?

There were five patients with diagnosed with advanced hepatocellular carcinoma stage C or D disease.

2. How many hepatocellular carcinoma patients (any stage) have been treated in the last 6 months with the following treatments:

- Lenvatinib
- Sorafenib
- Regorafenib
- Atezolizumab + Bevacizumab

The Trust is only able to provide information in relation to drug dispensing, we do not record diagnoses on our clinical systems so therefore we are unable to link the type of drug to diagnosis. Therefore, to extract this information, we would have to search through a significant amount of patient records. It is estimated that to attempt to retrieve all the information you require would take a considerable amount of retrieval time, which would exceed 18 hours. This would exceed the appropriate limit for dealing with a Freedom of Information Request, in terms of costs and therefore Section 12(1) of the Freedom of Information Act 2000 applies

3. In the last 6 months, how many patients has your trust treated (for any condition) with the following treatments:

Treatment	Patients
Avatrombopag	-
Eltrombopag	8
Fostamatinib	-
Romiplostim	7

4. In the last 6 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:

Treatment	Patients
Avatrombopag	0
Mycophenolate mofetil	0
Rituximab	<4
Surgery (splenectomy)	0

We are unable to provide precise figures when these are four or less due to the risk that individuals will be identified, as we are required to protect their identity under the Data Protection Act.

In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure.

5. Does your trust participate in any clinical trials for the treatment of hepatocellular carcinoma? If so, can you please provide the name of each trial and the number of patients taking part

The Trust does not participate in any clinical trials for the treatment of hepatocellular carcinoma.

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on Information.Governance@porthosp.nhs.uk or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team